Artgen

Artgen is a Russian biotechnology company. It was founded in 2003. It is engaged in scientific research, development of innovative drugs and high-tech services in the field of regenerative medicine, medical genetics, gene therapy, bioinsurance and biopharmaceuticals. It independently promotes his own developments in the market.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Artgen balance sheet

Report period2019 2020 2021 2022 2023 2024
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Artgen cash flows

Report period2019 2020 2021 2022 2023 2024
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
OIBDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Artgen multipliers

Report period2019 2020 2021 2022 2023 2024
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/OIBDA
EV/EBITDA
EV/OIBDA

Artgen profitability

Report period2019 2020 2021 2022 2023 2024
ROA
ROE
ROS
EBITDA Margin
Operating margin
Artgen assets
Artgen cash flows
Artgen dividends
2.14%

Artgen dividend policy

The recommended amount of dividend payments is determined based on year-end financial results, economic situation, and industry position and may range from 40% to 60% of net profit.

Artgen shares

TickerNameTypeNominal valueISINPrice
ABIO:RMArtgenCommon shareRUB 0.1RU000A0JNAB6RUB 79.38

Artgen bonds

NameIssue sizePriceYield
ISKJ BO-01 (RUB)300,000 pcs.87.8%20.90%
Share capital structure of Artgen
Artgen news
12.05.2025
Artgen's Board of Directors recommended not to pay dividends due to tight monetary policy and the challenges associated with continuing to finance the drugs under development.
Source: {source} pictogram artgen.ru
Pictogram next
07.05.2025
Board of Directors of Artgen Biotech terminated the agreement with Natsimbio on joint development of RBT vaccine for influenza and covid prophylaxis due to the delay in terms of organizing and conducting clinical trials. Ministry of Health allowed to conduct studies until December 31, 2024, but they never took place. Now RBT will independently prepare a doss...
Source: {source} pictogram artgen.ru
Pictogram next
28.04.2025
Artgen's IFRS net profit for 2024 amounted to ₽241.2 million, up 23.9% from ₽194.7 million in the previous year. Revenue rose 10.9% to ₽1.52 billion against ₽1.37 billion a year earlier.
Source: {source} pictogram e-disclosure.ru
Pictogram next
31.03.2025
Artgen's RAS net profit for 2024 amounted to ₽265.45 million, up 8.5% from ₽244.62 million in the previous year. Revenue rose 61.7% to ₽119.86 million against ₽74.14 million a year earlier.
Source: {source} pictogram e-disclosure.ru
Pictogram next
All Artgen news
General information
Company nameArtgen
Tags#biotechnology, #pharmacy, #innovations of the russia
SectorHealth Care / Health Care Equipment & Services / Health Care Providers & Services / Health Care Services
Business addressRF, g. Moskva
Mailing address117036, g. Moskva, prospekt 60-letiya Oktyabrya, d. 10A, etazh 3, pom. 24
CEOMasyuk Sergey Vladimirovich
Phone+7 (495) 646-80-76
Websiteartgen.ru
Information disclosuree-disclosure.ru